Accretion Nutraveda Investor Presentation: Key Takeaways
H1 FY27 (Apr–Sep 2026): revenue ₹29.44 Cr (+109.35% YoY), EBITDA ₹6.26 Cr (21.27% margin), PAT ₹4.73 Cr (16.06% margin). Focus on capacity expansion and product diversification.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
H1 FY27 (Apr–Sep 2026): revenue ₹29.44 Cr (+109.35% YoY), EBITDA ₹6.26 Cr (21.27% margin), PAT ₹4.73 Cr (16.06% margin). Focus on capacity expansion and product diversification.
Accretion Nutraveda released a half-year media release showing revenue up 109.35% to Rs 29.44 crore. EBITDA rose 88.03% and PAT rose 98.66%.
Accretion Nutraveda Ltd reported revenue from operations of ₹29.4 Cr (+108.5% YoY) and net profit of ₹4.7 Cr (+95.8% YoY) for H1 FY27.
Accretion Nutraveda's quarterly shareholding pattern shows promoters holding 73.48%. The routine filing reports no corporate action or event value.
Accretion Nutraveda will hold a board meeting on 31 October 2026 to consider unaudited financial results for the half year ended September 2026. The intimation is a prior notice under Regulation 29.
Accretion Nutraveda Limited announced results of its postal ballot. Shareholders approved special resolutions regarding MOA alteration, borrowing limits, and various loan and guarantee authorizations.
Accretion Nutraveda Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory disclosure under SEBI LODR.